Why Scholar Rock Holding Stock Topped the Market Today

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. This resulted in the stock bumping nearly 3% higher on the day. That handily beat the S&P 500 index, which itself had a good trading session with a 1.7% advance.

Bulking up

Scholar Rock targets relatively uncommon disorders that might lack effective treatments.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Its current lead drug candidate -- apitegromab, a medicine that preserves muscle mass in patients with two types of spinal muscular atrophy (SMA) -- is under review for approval by both the U.S. Food and Drug Administration and the European Union's European Medicines Agency (EMA).

Analyst Allison Bratzel of Piper Sandler feels that investors are not pricing apitegromab's potential into Scholar Rock's shares. According to reports, she wrote that if the drug well-received it could vault the biotech well higher in price; given that it's notably undervalued.

Accordingly, Bratzel maintained her overweight (buy, in other words) recommendation on Scholar Rock and her $42 per share price target.

Significant potential

Although there is no cure at present for SMA, drugs that promise to treat the more uncomfortable aspects of the disorder could indeed do very well. Since apitegromab has performed admirably in clinical trials, it certainly feels as if the treatment might become a go-to in the preservation of muscle mass for SMA patients.

That said, caution is always warranted for even the best biotech companies. The approvals Scholar Rock is seeking are by no means guaranteed, and a delay or denial in its current applications could batter the stock significantly. Investors should keep a sharp eye on regulatory developments with apitegromab.

Should you invest $1,000 in Scholar Rock right now?

Before you buy stock in Scholar Rock, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Scholar Rock wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $561,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $606,106!*

Now, it’s worth noting Stock Advisor’s total average return is 811% — a market-crushing outperformance compared to 153% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 21, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.